Pacira Biosciences, Inc. - 10-Q Summary (Q1 2011)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2011. Pacira Biosciences, Inc. (formerly Pacira Pharmaceuticals, Inc.) is an emerging specialty pharmaceutical company focused on its proprietary DepoFoam extended-release drug delivery technology. The company manufactures FDA-approved products DepoCyt(e) and DepoDur for commercial partners and is developing its lead product candidate, EXPAREL, for postsurgical analgesia. A New Drug Application (NDA) for EXPAREL was filed in September 2010, with a PDUFA decision goal date of July 28, 2011.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $3.86 million | $4.78 million |
| Net Loss | $(9.78) million | $(5.39) million |
| Net Loss Per Share (Basic/Diluted) | $(0.98) | $(9.39) |
| Cash and Cash Equivalents (End of Period) | $59.33 million | $10.57 million |
| Working Capital | $44.36 million | Not provided |
| Total Debt and Financing Obligations | $29.63 million | $79.42 million |
| Net Cash Used in Operating Activities | $(4.0) million | $(3.6) million |
Note: Gross margin on supply revenue was negative (-88%) due to excess manufacturing capacity costs. Excluding excess capacity, the margin was 41%.
Material Changes vs. Prior Period
- Initial Public Offering (IPO): On February 8, 2011, the company completed an IPO, raising $42.0 million in gross proceeds ($37.1 million net). This significantly improved liquidity, increasing cash balances from $26.1 million to $59.3 million.
- Debt Conversion: Upon the IPO closing, all outstanding Series A preferred stock and approximately $51.2 million in related party debt (convertible and secured notes) were converted into 10.66 million shares of common stock. Total debt obligations dropped from $79.4 million to $29.6 million.
- Revenue Decline: Total revenues decreased 19% to $3.86 million, driven primarily by a 35% drop in supply revenue for DepoCyt(e) due to the timing of manufacturing lot sales. Collaborative licensing revenue increased 25% due to a new agreement with Novo Nordisk.
- Expense Increases: Selling, general, and administrative (SG&A) expenses surged 276% to $3.8 million, largely due to stock-based compensation ($0.6 million) triggered by the IPO and hiring for commercial launch preparations. Research and development (R&D) expenses decreased 24% to $3.5 million following the closeout of pivotal Phase 3 trials for EXPAREL.
Outlook, Risks, and Management Commentary
- EXPAREL Approval: Management expects FDA approval for EXPAREL by the PDUFA goal date of July 28, 2011. Commercialization is anticipated to begin in the fourth quarter of 2011 if approved.
- Liquidity: With $59.3 million in cash, management believes resources are sufficient to fund operations through the end of 2011, even if EXPAREL is not approved, though additional financing may be required for long-term growth.
- New Partnership: In January 2011, Pacira entered a development and license agreement with Novo Nordisk, receiving a $1.5 million upfront fee and potential milestone payments up to $44 million.
- Risks: Key risks include the timing and outcome of the FDA review for EXPAREL, the need for additional capital if commercialization is delayed, and dependence on commercial partners for the sale of DepoCyt(e) and DepoDur. The company also faces currency risk from Euro-denominated sales.
Investor Verification Checklist
- EXPAREL FDA Decision: Verify the status of the NDA review and the July 28, 2011 PDUFA decision date.
- Cash Burn Rate: Monitor quarterly operating cash burn against the $59.3 million cash balance to assess runway without further financing.
- Debt Covenants: Review compliance with the Hercules Credit Facility covenants, particularly regarding the interest-only period ending August 31, 2011.
- Revenue Concentration: Note that the three largest customers accounted for 83% of Q1 2011 revenues; monitor stability of these partnerships.
- Commercial Readiness: Assess progress in hiring the sales force and building commercial infrastructure for the anticipated Q4 2011 launch.